Latest Insider Transactions at Revolution Medicines, Inc. (RVMD)
This section provides a real-time view of insider transactions for Revolution Medicines, Inc. (RVMD). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Revolution Medicines, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Revolution Medicines, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 17
2025
|
Mark A Goldsmith |
SELL
Open market or private sale
|
Direct |
10,000
-2.16%
|
$550,000
$55.0 P/Share
|
|
Oct 17
2025
|
Mark A Goldsmith |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.12%
|
$10,000
$1.12 P/Share
|
|
Oct 17
2025
|
Jeff Cislini General Counsel |
SELL
Open market or private sale
|
Direct |
12,000
-19.22%
|
$660,000
$55.0 P/Share
|
|
Oct 17
2025
|
Jeff Cislini General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+16.12%
|
$432,000
$36.57 P/Share
|
|
Oct 16
2025
|
Mark A Goldsmith |
SELL
Open market or private sale
|
Direct |
10,000
-2.16%
|
$500,000
$50.47 P/Share
|
|
Oct 16
2025
|
Mark A Goldsmith |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.12%
|
$10,000
$1.12 P/Share
|
|
Oct 13
2025
|
Stephen Michael Kelsey |
SELL
Open market or private sale
|
Direct |
25,000
-8.09%
|
$1,200,000
$48.54 P/Share
|
|
Oct 13
2025
|
Stephen Michael Kelsey |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+7.48%
|
$100,000
$4.73 P/Share
|
|
Sep 24
2025
|
Jeff Cislini General Counsel |
SELL
Open market or private sale
|
Direct |
1,799
-3.44%
|
$79,156
$44.26 P/Share
|
|
Sep 16
2025
|
Lin Wei Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,160
-2.39%
|
$97,200
$45.82 P/Share
|
|
Sep 16
2025
|
Jack Anders Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,320
-2.05%
|
$104,400
$45.82 P/Share
|
|
Sep 16
2025
|
Jeff Cislini General Counsel |
SELL
Open market or private sale
|
Direct |
1,869
-3.46%
|
$84,105
$45.82 P/Share
|
|
Sep 16
2025
|
Margaret A Horn Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
4,775
-3.17%
|
$214,875
$45.82 P/Share
|
|
Sep 16
2025
|
Mark A Goldsmith |
SELL
Open market or private sale
|
Direct |
13,411
-2.88%
|
$603,495
$45.82 P/Share
|
|
Sep 16
2025
|
Stephen Michael Kelsey |
SELL
Open market or private sale
|
Direct |
5,367
-1.85%
|
$241,515
$45.82 P/Share
|
|
Sep 15
2025
|
Stephen Michael Kelsey |
SELL
Open market or private sale
|
Direct |
25,000
-3.99%
|
$1,150,000
$46.42 P/Share
|
|
Sep 15
2025
|
Stephen Michael Kelsey |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+7.37%
|
$100,000
$4.73 P/Share
|
|
Sep 11
2025
|
Stephen Michael Kelsey |
SELL
Open market or private sale
|
Direct |
100,000
-13.76%
|
$4,400,000
$44.03 P/Share
|
|
Sep 11
2025
|
Stephen Michael Kelsey |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+20.43%
|
$400,000
$4.73 P/Share
|
|
Sep 03
2025
|
Jack Anders Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,238
-4.42%
|
$209,520
$40.17 P/Share
|
|
Sep 03
2025
|
Jack Anders Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,238
+2.18%
|
$52,380
$10.87 P/Share
|
|
Sep 02
2025
|
Jack Anders Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,762
-4.03%
|
$190,480
$40.02 P/Share
|
|
Sep 02
2025
|
Jack Anders Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,762
+1.99%
|
$14,286
$3.71 P/Share
|
|
Jun 30
2025
|
Mark A Goldsmith |
BUY
Exercise of conversion of derivative security
|
Direct |
37,000
+7.36%
|
$0
$0.54 P/Share
|
|
Jun 26
2025
|
Alexis Borisy |
BUY
Grant, award, or other acquisition
|
Direct |
3,142
+0.13%
|
-
|
|
Jun 26
2025
|
Lorence H. Kim |
BUY
Grant, award, or other acquisition
|
Direct |
3,142
+4.12%
|
-
|
|
Jun 26
2025
|
Sushil Patel |
BUY
Grant, award, or other acquisition
|
Direct |
3,142
+11.98%
|
-
|
|
Jun 26
2025
|
Sandra Horning |
BUY
Grant, award, or other acquisition
|
Direct |
3,142
+3.15%
|
-
|
|
Jun 26
2025
|
Frank Clyburn |
BUY
Grant, award, or other acquisition
|
Direct |
2,806
+22.37%
|
-
|
|
Jun 26
2025
|
Elizabeth M Anderson |
BUY
Grant, award, or other acquisition
|
Direct |
3,142
+11.92%
|
-
|
|
Jun 26
2025
|
Flavia Borellini |
BUY
Grant, award, or other acquisition
|
Direct |
3,142
+11.16%
|
-
|
|
Jun 20
2025
|
Jeff Cislini General Counsel |
SELL
Open market or private sale
|
Direct |
1,912
-3.41%
|
$74,568
$39.61 P/Share
|
|
Jun 16
2025
|
Lin Wei Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,173
-2.34%
|
$84,747
$39.83 P/Share
|
|
Jun 16
2025
|
Stephen Michael Kelsey |
SELL
Open market or private sale
|
Direct |
4,289
-1.46%
|
$167,271
$39.83 P/Share
|
|
Jun 16
2025
|
Jack Anders Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,170
-1.88%
|
$84,630
$39.83 P/Share
|
|
Jun 16
2025
|
Jeff Cislini General Counsel |
SELL
Open market or private sale
|
Direct |
1,878
-3.24%
|
$73,242
$39.83 P/Share
|
|
Jun 16
2025
|
Mark A Goldsmith |
SELL
Open market or private sale
|
Direct |
13,496
-3.05%
|
$526,344
$39.83 P/Share
|
|
Jun 16
2025
|
Margaret A Horn Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,510
-2.28%
|
$136,890
$39.83 P/Share
|
|
Mar 20
2025
|
Jeff Cislini General Counsel |
SELL
Open market or private sale
|
Direct |
2,041
-3.42%
|
$77,558
$38.71 P/Share
|
|
Mar 17
2025
|
Xiaolin Wang |
SELL
Bona fide gift
|
Direct |
2,718
-2.59%
|
-
|
|
Mar 17
2025
|
Stephen Michael Kelsey |
SELL
Open market or private sale
|
Direct |
3,294
-1.11%
|
$128,466
$39.04 P/Share
|
|
Mar 17
2025
|
Margaret A Horn Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,058
-1.95%
|
$119,262
$39.04 P/Share
|
|
Mar 17
2025
|
Jack Anders Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,864
-1.59%
|
$72,696
$39.04 P/Share
|
|
Mar 17
2025
|
Mark A Goldsmith |
SELL
Open market or private sale
|
Direct |
11,738
-2.59%
|
$457,782
$39.04 P/Share
|
|
Mar 17
2025
|
Jeff Cislini General Counsel |
SELL
Open market or private sale
|
Direct |
1,458
-2.38%
|
$56,862
$39.04 P/Share
|
|
Mar 01
2025
|
Mark A Goldsmith |
BUY
Grant, award, or other acquisition
|
Direct |
97,400
+17.69%
|
-
|
|
Mar 01
2025
|
Xiaolin Wang |
BUY
Grant, award, or other acquisition
|
Direct |
19,000
+15.32%
|
-
|
|
Mar 01
2025
|
Lin Wei Chief Medical Officer |
SELL
Grant, award, or other acquisition
|
Direct |
20,800
-18.5%
|
-
|
|
Mar 01
2025
|
Margaret A Horn Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,600
+15.44%
|
-
|
|
Mar 01
2025
|
Stephen Michael Kelsey |
BUY
Grant, award, or other acquisition
|
Direct |
36,600
+10.99%
|
-
|